Cystic Fibrosis News Today Weekly Digest

Cystic Fibrosis Weekly Update Contents: Viral Respiratory Tract Infections in Young CF Children Usually Mild, Study Found FDA Designates Vast’s BIOC11 a Qualified Infectious Disease Product Viral Respiratory Tract Infections in Young CF Children Usually Mild, Study Found Oct 11, 2019 07:00 am | Alejandra Viviescas PhD Viral respiratory tract infections in young children with cystic fibrosis tend to be mild and not require hospitalization, a study found. Infections caused by respiratory syncytial virus (RSV) were rare and did not lead to complications, suggesting that there is no need for preventive medication such as Synagis (palivizumab) in this young population. The study, […] The post Viral Respiratory Tract Infections in Young CF Children Usually Mild, Study Found appeared first on Cystic Fibrosis News Today. Read More FDA Designates Vast’s BIOC11 a Qualified Infectious Disease Product Oct 10, 2019 07:00 am | Marisa Wexler MS The U.S. Food and Drug Administration (FDA) has designated Vast Therapeutics’ BIOC11 a Qualified Infectious Disease Product (QIDP) for the treatment of people with cystic fibrosis (CF) who have chronic pulmonary infections due to Pseudomonas aeruginosa. The QIDP designation makes BIOC11 eligible for priority-review and fast-track statuses that can speed the therapy’s development. BIOC11 uses nitric […] The post FDA Designates Vast’s BIOC11 a Qualified Infectious Disease Product appeared first on Cystic Fibrosis News Today. Read More Recent News Scientists Hope They Have Discovered New Form of CF Therapy Sorry Not Sorry That I’m Sick Experts Highlight Obstacles in Delivering New CF Therapies Debunking the Myths About Vaccine Safety 5,000 Expected to Attend Cystic Fibrosis Conference, NACFC 2019, in Nashville